Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

Research output: Contribution to journalArticlepeer-review

373 Downloads (Pure)
Original languageEnglish
Pages (from-to)1073-1084
Number of pages12
JournalThe Lancet
Volume371
Issue number9618
DOIs
Publication statusPublished - 29 Mar 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this